Investing.com - Perspective Therapeutics (NYSE: CATX) reported first quarter EPS of $-0.2100, in line with the analyst estimate of $-0.2100. Revenue for the quarter came in at $369K versus the consensus estimate of $191.73K.
Perspective Therapeutics's stock price closed at $10.60. It is down -21.3900% in the last 3 months and up 353.5900% in the last 12 months.
Perspective Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Perspective Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Perspective Therapeutics's Financial Health score is "fair performance".
Check out Perspective Therapeutics's recent earnings performance, and Perspective Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar